Amneal Raises FY23 Revenue Guidance To $2.30B-$2.40B Vs. Consensus Of $2.32B And Prior Guidance Of $2.25B-$2.35B, It Forecasts Adjusted EPS Of $0.45-$0.55 Vs. Consensus Of $0.47 And Prior Guidance Of $0.40-$0.50
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals has raised its FY23 revenue guidance to $2.30B-$2.40B, up from the previous guidance of $2.25B-$2.35B. The new guidance surpasses the consensus estimate of $2.32B. The company also increased its adjusted EPS forecast to $0.45-$0.55, up from $0.40-$0.50, beating the consensus estimate of $0.47.
August 04, 2023 | 2:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amneal's raised FY23 revenue and EPS guidance, which surpass consensus estimates, could positively impact its stock price in the short term.
Companies that raise their guidance typically see a positive reaction in their stock price, especially when the new guidance surpasses consensus estimates. This is because the raised guidance signals the company's confidence in its future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100